Luminec Pharmaceuticals Submits New Evidence for NIH, BARDA Coronavirus Application

Share Article

Recent case studies underscore the efficacy of Luminec formulations

Dr. Susana Alcázar-Leyva

Based on these new studies, we believe that X-2 and CRO-50 can make a significant contribution in the treatment of the novel Coronavirus.

As part of its application for consideration to the National Institute of Allergies and Infectious Diseases (NIAID) and to the Biomedical Advanced Research and Development Authority (BARDA), Luminec Pharmaceuticals is submitting new case studies showing strong evidence of the efficacy of our combined therapy of CRO-50 (ribonuclease) and X-2 (stable thiamine formulation) in COVID-19 patients, as well as in other Coronavirus patients.

These case studies were compiled by Luminec Executive Board Member Susana Alcázar-Leyva, MD, PhD, based on her first-hand experience with patients around the world. According to Dr. Alcázar-Leyva, “Based on these new studies, we believe that X-2 and CRO-50 can make a significant contribution in the treatment of the novel Coronavirus.”

In addition to her role with Luminec Pharmaceuticals, Dr. Alcázar-Leyva is a founding director of the prestigious Hans Selye Scientific Research Institute, and cofounder and director of the Heberto Alcázar-Montenegro Gerontology School (cofounded by, and named for, her father), and of the Albert Szent-Györgyi Gerontology Center.

Stephen Holt, MD, DSc, PhD, Luminec chief science officer, commented, “We are presenting Dr. Alcázar-Leyva’s findings to BARDA and NIAID to support our application in the hopes that our protocols will be cleared for a regulatory pathway to FDA approval.” Dr. Holt noted that Luminec Pharmaceuticals is also making a similar submission to the Israel National Institute for Health Policy Research (NIHP) for consideration in their battle with the Coronavirus.

About Luminec Pharmaceuticals

Headquartered in Carlsbad, CA, Luminec Pharmaceuticals currently offers a unique array of all-natural OTC products and clinical services for both human and animal use. Luminec’s products include natural proprietary formulations based on the Schutt Paradigm of Free Amino Ion Alignment & Molecular Stability, in combination with proprietary partner technologies with a cutting edge delivery technology, oral and topically, composed of charged delivery spheres that encapsulate and transport active compounds into the system, naturally.

Luminec Pharmaceuticals is a wholly owned subsidiary of Luminec Holding Corporation, a private company.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Jay Mitchell
Visit website